These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 39270429)

  • 1. Central nervous system involvement in Erdheim-Chester disease: a magnetic resonance imaging study.
    Zahergivar A; Firouzabadi FD; Homayounieh F; Golagha M; Huda F; Biassou N; Shah R; Nikpanah M; Mirmomen M; Farhadi F; Dave RH; Shekhar S; Gahl WA; Estrada-Veras JI; Malayeri AA; O'Brien K
    Clin Imaging; 2024 Nov; 115():110281. PubMed ID: 39270429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
    Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAF
    Mirmomen SM; Sirajuddin A; Nikpanah M; Symons R; Paschall AK; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Nov; 28(11):4635-4642. PubMed ID: 29736852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system involvement in Erdheim-Chester disease: An observational cohort study.
    Cohen Aubart F; Idbaih A; Galanaud D; Law-Ye B; Emile JF; Charlotte F; Donadieu J; Maksud P; Seilhean D; Amoura Z; Hoang-Xuan K; Haroche J
    Neurology; 2020 Nov; 95(20):e2746-e2754. PubMed ID: 32887776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
    Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
    Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoalphalipoproteinemia and BRAF
    Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Young JR; Johnson GB; Murphy RC; Go RS; Broski SM
    J Nucl Med; 2018 May; 59(5):774-779. PubMed ID: 29097410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal involvement in Erdheim-Chester disease: Multimodality imaging features and association with the BRAF
    Nikpanah M; Dehghani Firouzabadi F; Farhadi F; Mirmomen SM; Ahlman MA; Huda F; Millo C; Saboury B; Paschall AK; Gahl WA; Estrada-Veras JI; Turkbey E; Jones EC; O'Brien K; Malayeri AA
    Clin Imaging; 2024 Feb; 106():110067. PubMed ID: 38128404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.
    Hoyt BS; Yan S; Linos KD; Momtahen S; Sriharan A; Tran TN; Tsongalis GJ; O'Meara RR; Green DC; LeBlanc RE
    Exp Mol Pathol; 2019 Dec; 111():104320. PubMed ID: 31639332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Neuroimaging Manifestations of Erdheim-Chester Disease: A Review.
    Garg N; Lavi ES
    J Neuroimaging; 2021 Jan; 31(1):35-44. PubMed ID: 32920940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
    Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT
    Per Med; 2024; 21(2):71-78. PubMed ID: 38275171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neuroimaging features of histiocytic neoplasms with central nervous system involvement: a retrospective study of 121 adult patients.
    Fan X; Liu T; Zhang Z; Sun J; Niu N; Mao C; Wang F; Li J; Zhou D; Cao X; Jin Z; Feng F
    Eur Radiol; 2023 Nov; 33(11):8031-8042. PubMed ID: 37191919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
    Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
    Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.
    Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J
    Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
    Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
    Front Immunol; 2022; 13():918613. PubMed ID: 35874752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib as first-line therapy in
    Fernández-Eulate G; Muñoz-Lopetegi A; Ruiz I; Urtasun M
    BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31748352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.